Dry Eye Sufferers Find Breakthrough Treatment at New Northwest Dry Eye Center

Share Article

New Bellevue clinic is the first center in the state of Washington to offer revolutionary technology from TearScience to assess and treat Evaporative Dry Eye

Northwest Dry Eye Center in Bellevue

"I believe that LipiFlow and other technology innovations from TearScience will in the next several years safely improve the lives of tens of thousands, and in this decade millions of dry eye sufferers." said Dr. Donald R. Korb, co-founder of TearScience.

Endless eye drops and constant warm compresses to suppress scratchy, gritty and dry eyes are no longer the only treatments available to Seattle-area sufferers of a chronic, progressive condition known as Evaporative Dry Eye thanks to the opening of the Northwest Dry Eye Center in Bellevue, WA. Opened by Dr. Paul Jensen, an optometric physician who has been practicing in Renton since 1986, the new Northwest Dry Eye Center is the first Washington clinic to offer LipiFlow®, a breakthrough treatment for evaporative dry eye disease from TearScience. Headquartered in Morrisville, NC, TearScience’s innovative technology assesses and treats the root cause of Evaporative Dry Eye disease and is the result of 30 years of research and collaboration and millions of dollars of investment.

Dr. Jensen’s clinic will also offer innovative treatments for other dry eye ailments, including nutraceuticals, punctual plugs, scleral lenses and prescription medications to treat different forms of dry eye disease.

“Today, patients have reported only marginal relief when using traditional dry eye therapies such as warm compresses and over-the-counter wetting drops. Patients and doctors have eagerly awaited for a new and improved standard of care when it comes to treating evaporative dry eye,” said Jensen, who happens to also suffer from dry eye. “Co-founded by one of the most respected optometrist in the world, Dr. Donald R. Korb, TearScience offers that new standard and dramatically improves the ability to help patients.”

TearScience gained FDA clearance in February 2012 for its system that assesses and treats Evaporative Dry Eye, which occurs when Meibomian glands in the eyelids become obstructed and do not secrete the oily lipids needed to keep the water portion of tears from evaporating too quickly. TearScience’s assessment and treatment devices include, the LipiView® Ocular Surface Interferometer and the LipiFlow ® Thermal Pulsation System. LipiView provides measures the absolute thickness of the lipid layer of a dry eye patient’s tear film. LipiView may be used by a physician in conjunction with a dry eye questionnaire and a Meibomian gland evaluation to determine if a patient suffers from Evaporative Dry Eye. LipiView also helps identify if the patient is a partial blinker, which results in the eye not being properly lubricated during blinks.

For patients who suffer from Evaporative Dry Disease, which can cause eyes to feel dry, irritated, gritty and may even cause blurred vision or sensitivity to sunlight, LipiFlow can be used to treat a root cause by unblocking obstructed Meibomian glands located in the eyelids during an in-office procedure. The goal of unblocking the Meibomian glands is to allow them to resume their natural production of lipids for a healthy tear film. Evaporative Dry Eye differs from Aqueous Deficient Dry Eye, where the body is not able to produce adequate moisture to keep the eyes lubricated and are typically treated with pharmaceuticals like Restasis. According to a recent study, 86 percent of dry eye patients suffer from Evaporative Dry Eye. Left untreated, Evaporative Dry Eye is a chronic, progressive disease that may worsen over time. Patients who undergo a LipiView screening gain a better understanding of their disease to make informed decisions about treatment options.

"I believe that LipiFlow and other technology innovations from TearScience will in the next several years safely improve the lives of tens of thousands, and in this decade millions of dry eye sufferers,” said Dr. Donald R. Korb, co-founder of TearScience. “This projection is based upon both my research and clinical practice, where I can personally observe the quantum leaps in treatment of dry eye."

Having extensively lectured, written, and taught doctors and interns regarding the treatment of dry eye, Dr. Jensen intends for the Northwest Dry Eye center to serve as a hub for other optometrists and ophthalmologists to send their patients for evaluation and treatment. In most evaporative dry eye cases, Dr. Jensen believes most patients can be assessed and treated for less money than they currently spend annually on drops. In TearScience’s multi-center, randomized, controlled clinical study, 79 percent of patients who received a single LipiFlow® treatment reported improvements in overall dry eye symptoms.

“My eyes were red, scratchy and obvious to others that I had some type of eye issues, including have some of my colleagues even questioned if I had pink eye,” said Ms. Joy Murray, a dry eye patient treated by Jensen. “Immediately after being treated with LipiFlow, I had relief and my eyes were noticeably different. Today I am noticeably clearer than prior to treatment and my comfort level is what I would classify as a 100 percent. The process was very quick and easy and the staff and Dr. Jensen were very respectful, informative and professional.”

To hear more TearScience customer testimonials, click here.

1.     Lemp MA, et al. Distribution of aqueous deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012:31(5):472-478

About Northwest Dry Eye Center
Northwest Dry Eye Center utilizes breakthrough technology to assess and treat dry eye disease. Founded by Dr. Paul Jensen, an optometric physician who has been practicing in Renton since 1986, Northwest Dry Center treats mild to severe dry eye, as well as provides resources and training for eye doctors and others in the dry eye community. For more information, visit http://www.nwdryeyecenter.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Paul Jensenl
Visit website